{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:48:11Z","timestamp":1795085291305,"version":"4.10.2"},"reference-count":284,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Mol Cell Biol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1038\/s41580-023-00631-w","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T09:02:35Z","timestamp":1690275755000},"page":"816-834","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":519,"title":["Biology and therapeutic targeting of vascular endothelial growth factor A"],"prefix":"10.1038","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8135-4975","authenticated-orcid":false,"given":"Lorena","family":"P\u00e9rez-Guti\u00e9rrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Napoleone","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"key":"631_CR1","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1126\/science.2432664","volume":"235","author":"J Folkman","year":"1987","unstructured":"Folkman, J. & Klagsbrun, M. Angiogenic factors. Science 235, 442\u2013447 (1987).","journal-title":"Science"},{"key":"631_CR2","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cell.2011.08.039","volume":"146","author":"M Potente","year":"2011","unstructured":"Potente, M., Gerhardt, H. & Carmeliet, P. Basic and therapeutic aspects of angiogenesis. Cell 146, 873\u2013887 (2011).","journal-title":"Cell"},{"key":"631_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10456-023-09876-7","volume":"26","author":"AC Dudley","year":"2023","unstructured":"Dudley, A. C. & Griffioen, A. W. Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis 26, 313\u2013347\u00a0(2023).","journal-title":"Angiogenesis"},{"key":"631_CR4","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1161\/CIRCULATIONAHA.119.041433","volume":"142","author":"DT Paik","year":"2020","unstructured":"Paik, D. T. et al. Single-cell RNA sequencing unveils unique transcriptomic signatures of organ-specific endothelial cells. Circulation 142, 1848\u20131862 (2020).","journal-title":"Circulation"},{"key":"631_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41569-020-0359-y","volume":"17","author":"DT Paik","year":"2020","unstructured":"Paik, D. T., Cho, S., Tian, L., Chang, H. Y. & Wu, J. C. Single-cell RNA sequencing in cardiovascular development, disease and medicine. Nat. Rev. Cardiol. 17, 457\u2013473 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"631_CR6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.cmet.2020.03.009","volume":"31","author":"K Rohlenova","year":"2020","unstructured":"Rohlenova, K. et al. Single-cell RNA sequencing maps endothelial metabolic plasticity in pathological angiogenesis. Cell Metab. 31, 862\u2013877.e14 (2020).","journal-title":"Cell Metab."},{"key":"631_CR7","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","volume":"22","author":"Y Cao","year":"2023","unstructured":"Cao, Y., Langer, R. & Ferrara, N. Targeting angiogenesis in oncology, ophthalmology and beyond. Nat. Rev. Drug Discov. 22, 476\u2013495\u00a0(2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"631_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1146\/annurev.cb.11.110195.000445","volume":"11","author":"W Risau","year":"1995","unstructured":"Risau, W. & Flamme, I. Vasculogenesis. Ann. Rev. Cell Dev. Biol. 11, 73\u201391 (1995).","journal-title":"Ann. Rev. Cell Dev. Biol."},{"key":"631_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1146\/annurev-cellbio-092910-154002","volume":"27","author":"AS Chung","year":"2011","unstructured":"Chung, A. S. & Ferrara, N. Developmental and pathological angiogenesis. Annu. Rev. Cell Dev. Biol. 27, 563\u2013584 (2011).","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"631_CR10","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrm2183","volume":"8","author":"RH Adams","year":"2007","unstructured":"Adams, R. H. & Alitalo, K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 8, 464\u2013478 (2007).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"631_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581\u2013611 (2004).","journal-title":"Endocr. Rev."},{"key":"631_CR12","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nature04479","volume":"438","author":"L Coultas","year":"2005","unstructured":"Coultas, L., Chawengsaksophak, K. & Rossant, J. Endothelial cells and VEGF in vascular development. Nature 438, 937\u2013945 (2005).","journal-title":"Nature"},{"key":"631_CR13","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrm.2016.87","volume":"17","author":"M Simons","year":"2016","unstructured":"Simons, M., Gordon, E. & Claesson-Welsh, L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat. Rev. Mol. Cell Biol. 17, 611\u2013625 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"631_CR14","doi-asserted-by":"publisher","first-page":"9267","DOI":"10.1073\/pnas.88.20.9267","volume":"88","author":"D Maglione","year":"1991","unstructured":"Maglione, D., Guerriero, V., Viglietto, G., Delli-Bovi, P. & Persico, M. G. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl Acad. Sci. USA 88, 9267\u20139271 (1991).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR15","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1073\/pnas.93.6.2576","volume":"93","author":"B Olofsson","year":"1996","unstructured":"Olofsson, B. et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl Acad. Sci. USA 93, 2576\u20132581 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR16","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/j.1460-2075.1996.tb00521.x","volume":"15","author":"V Joukov","year":"1996","unstructured":"Joukov, V. et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15, 1751 (1996).","journal-title":"EMBO J."},{"key":"631_CR17","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1073\/pnas.95.2.548","volume":"95","author":"MG Achen","year":"1998","unstructured":"Achen, M. G. et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl Acad. Sci. USA 95, 548\u2013553 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1128\/jvi.68.1.84-92.1994","volume":"68","author":"DJ Lyttle","year":"1994","unstructured":"Lyttle, D. J., Fraser, K. M., Flemings, S. B., Mercer, A. A. & Robinson, A. J. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J. Virol. 68, 84\u201392 (1994).","journal-title":"J. Virol."},{"key":"631_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/emboj\/18.2.363","volume":"18","author":"M Meyer","year":"1999","unstructured":"Meyer, M. et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 18, 363\u2013374 (1999).","journal-title":"EMBO J."},{"key":"631_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10456-023-09874-9","volume":"26","author":"K Rauniyar","year":"2023","unstructured":"Rauniyar, K., Bokharaie, H. & Jeltsch, M. Expansion and collapse of VEGF diversity in major clades of the animal kingdom. Angiogenesis 26, 437\u2013461\u00a0(2023).","journal-title":"Angiogenesis"},{"key":"631_CR21","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0006-291X(89)92678-8","volume":"161","author":"N Ferrara","year":"1989","unstructured":"Ferrara, N. & Henzel, W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161, 851\u2013858 (1989).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"631_CR22","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1126\/science.2479986","volume":"246","author":"DW Leung","year":"1989","unstructured":"Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306\u20131309 (1989).","journal-title":"Science"},{"key":"631_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1128\/MCB.25.1.355-363.2005","volume":"25","author":"S Hiratsuka","year":"2005","unstructured":"Hiratsuka, S. et al. Vascular endothelial growth factor A (VEGF-A) is involved in guidance of VEGF receptor-positive cells to the anterior portion of early embryos. Mol. Cell Biol. 25, 355\u2013363 (2005).","journal-title":"Mol. Cell Biol."},{"key":"631_CR24","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 9, 669\u2013676 (2003).","journal-title":"Nat. Med."},{"key":"631_CR25","doi-asserted-by":"publisher","first-page":"8761","DOI":"10.1073\/pnas.94.16.8761","volume":"94","author":"LE Benjamin","year":"1997","unstructured":"Benjamin, L. E. & Keshet, E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl Acad. Sci. USA 94, 8761\u20138766 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1146\/annurev-neuro-111020-102127","volume":"45","author":"A Rattner","year":"2022","unstructured":"Rattner, A., Wang, Y. & Nathans, J. Signaling pathways in neurovascular development. Annu. Rev. Neurosci. 45, 87\u2013108 (2022).","journal-title":"Annu. Rev. Neurosci."},{"key":"631_CR27","doi-asserted-by":"publisher","first-page":"11947","DOI":"10.1016\/S0021-9258(18)99049-6","volume":"266","author":"E Tischer","year":"1991","unstructured":"Tischer, E. et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266, 11947\u201311954 (1991).","journal-title":"J. Biol. Chem."},{"key":"631_CR28","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1210\/mend-5-12-1806","volume":"5","author":"KA Houck","year":"1991","unstructured":"Houck, K. A. et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5, 1806\u20131814 (1991).","journal-title":"Mol. Endocrinol."},{"key":"631_CR29","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.1074\/jbc.272.11.7151","volume":"272","author":"Z Poltorak","year":"1997","unstructured":"Poltorak, Z. et al. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem. 272, 7151\u20137158 (1997).","journal-title":"J. Biol. Chem."},{"key":"631_CR30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1091\/mbc.e09-07-0590","volume":"21","author":"N Ferrara","year":"2010","unstructured":"Ferrara, N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol. Biol. Cell 21, 687\u2013690 (2010).","journal-title":"Mol. Biol. Cell"},{"key":"631_CR31","doi-asserted-by":"publisher","first-page":"26031","DOI":"10.1016\/S0021-9258(18)35712-0","volume":"267","author":"KA Houck","year":"1992","unstructured":"Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J. & Ferrara, N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267, 26031\u201326037 (1992).","journal-title":"J. Biol. Chem."},{"key":"631_CR32","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1091\/mbc.4.12.1317","volume":"4","author":"JE Park","year":"1993","unstructured":"Park, J. E., Keller, G. A. & Ferrara, N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4, 1317\u20131326 (1993).","journal-title":"Mol. Biol. Cell"},{"key":"631_CR33","doi-asserted-by":"publisher","first-page":"7788","DOI":"10.1074\/jbc.271.13.7788","volume":"271","author":"BA Keyt","year":"1996","unstructured":"Keyt, B. A. et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. 271, 7788\u20137795 (1996).","journal-title":"J. Biol. Chem."},{"key":"631_CR34","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1083\/jcb.200409115","volume":"169","author":"S Lee","year":"2005","unstructured":"Lee, S., Jilani, S. M., Nikolova, G. V., Carpizo, D. & Iruela-Arispe, M. L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol. 169, 681\u2013691 (2005).","journal-title":"J. Cell Biol."},{"key":"631_CR35","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860\u2013867 (2002).","journal-title":"Nature"},{"key":"631_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/biology10020167","volume":"10","author":"J Kunnapuu","year":"2021","unstructured":"Kunnapuu, J., Bokharaie, H. & Jeltsch, M. Proteolytic cleavages in the VEGF family: generating diversity among angiogenic VEGFs, essential for the activation of lymphangiogenic VEGFs. Biology\u00a010, 167\u00a0(2021).","journal-title":"Biology"},{"key":"631_CR37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/8379","volume":"5","author":"P Carmeliet","year":"1999","unstructured":"Carmeliet, P. et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. 5, 495\u2013502 (1999).","journal-title":"Nat. Med."},{"key":"631_CR38","first-page":"4123","volume":"62","author":"DO Bates","year":"2002","unstructured":"Bates, D. O. et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 62, 4123\u20134131 (2002).","journal-title":"Cancer Res."},{"key":"631_CR39","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/nrc2505","volume":"8","author":"SJ Harper","year":"2008","unstructured":"Harper, S. J. & Bates, D. O. VEGF-A splicing: the key to anti-angiogenic therapeutics. Nat. Rev. Cancer 8, 880\u2013887 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"631_CR40","doi-asserted-by":"publisher","first-page":"7822","DOI":"10.1158\/0008-5472.CAN-04-0934","volume":"64","author":"J Woolard","year":"2004","unstructured":"Woolard, J. et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64, 7822\u20137835 (2004).","journal-title":"Cancer Res."},{"key":"631_CR41","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/nm.3703","volume":"20","author":"R Kikuchi","year":"2014","unstructured":"Kikuchi, R. et al. An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease. Nat. Med. 20, 1464\u20131471 (2014).","journal-title":"Nat. Med."},{"key":"631_CR42","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1158\/0008-5472.CAN-07-6577","volume":"68","author":"H Kawamura","year":"2008","unstructured":"Kawamura, H., Li, X., Harper, S. J., Bates, D. O. & Claesson-Welsh, L. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res. 68, 4683\u20134692 (2008).","journal-title":"Cancer Res."},{"key":"631_CR43","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.tem.2020.01.014","volume":"31","author":"H Dardente","year":"2020","unstructured":"Dardente, H., English, W. R., Valluru, M. K., Kanthou, C. & Simpson, D. Debunking the myth of the endogenous antiangiogenic Vegfaxxxb transcripts. Trends Endocrinol. Metab. 31, 398\u2013409 (2020).","journal-title":"Trends Endocrinol. Metab."},{"key":"631_CR44","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/j.cell.2014.04.033","volume":"157","author":"SM Eswarappa","year":"2014","unstructured":"Eswarappa, S. M. et al. Programmed translational readthrough generates antiangiogenic VEGF-Ax. Cell 157, 1605\u20131618 (2014).","journal-title":"Cell"},{"key":"631_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.cell.2016.08.054","volume":"167","author":"H Xin","year":"2016","unstructured":"Xin, H., Zhong, C., Nudleman, E. & Ferrara, N. Evidence for pro-angiogenic functions of VEGF-Ax. Cell 167, 275\u2013284.e6 (2016).","journal-title":"Cell"},{"key":"631_CR46","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/359843a0","volume":"359","author":"D Shweiki","year":"1992","unstructured":"Shweiki, D., Itin, A., Soffer, D. & Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843\u2013845 (1992).","journal-title":"Nature"},{"key":"631_CR47","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.immuni.2014.09.008","volume":"41","author":"A Palazon","year":"2014","unstructured":"Palazon, A., Goldrath, A. W., Nizet, V. & Johnson, R. S. HIF transcription factors, inflammation, and immunity. Immunity 41, 518\u2013528 (2014).","journal-title":"Immunity"},{"key":"631_CR48","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1177\/1947601911423654","volume":"2","author":"BL Krock","year":"2011","unstructured":"Krock, B. L., Skuli, N. & Simon, M. C. Hypoxia-induced angiogenesis: good and evil. Genes Cancer 2, 1117\u20131133 (2011).","journal-title":"Genes Cancer"},{"key":"631_CR49","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1128\/MCB.16.9.4604","volume":"16","author":"JA Forsythe","year":"1996","unstructured":"Forsythe, J. A. et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16, 4604\u20134613 (1996).","journal-title":"Mol. Cell. Biol."},{"key":"631_CR50","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1161\/01.RES.0000102937.50486.1B","volume":"93","author":"BD Kelly","year":"2003","unstructured":"Kelly, B. D. et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ. Res. 93, 1074\u20131081 (2003).","journal-title":"Circ. Res."},{"key":"631_CR51","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc2502","volume":"8","author":"WG Kaelin Jr.","year":"2008","unstructured":"Kaelin, W. G. Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer 8, 865\u2013873 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"631_CR52","doi-asserted-by":"publisher","first-page":"C812","DOI":"10.1152\/ajpcell.1999.276.4.C812","volume":"276","author":"S Fischer","year":"1999","unstructured":"Fischer, S. et al. Hypoxia induces permeability in brain microvessel endothelial cells via VEGF and NO. Am. J. Physiol. 276, C812\u2013C820 (1999).","journal-title":"Am. J. Physiol."},{"key":"631_CR53","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.freeradbiomed.2009.03.027","volume":"47","author":"DC Irwin","year":"2009","unstructured":"Irwin, D. C. et al. A potential role for reactive oxygen species and the HIF-1\u03b1-VEGF pathway in hypoxia-induced pulmonary vascular leak. Free Radic. Biol. Med. 47, 55\u201361 (2009).","journal-title":"Free Radic. Biol. Med."},{"key":"631_CR54","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccr.2004.09.026","volume":"6","author":"N Tang","year":"2004","unstructured":"Tang, N. et al. Loss of HIF-1\u03b1 in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6, 485\u2013495 (2004).","journal-title":"Cancer Cell"},{"key":"631_CR55","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1093\/emboj\/17.11.3005","volume":"17","author":"HE Ryan","year":"1998","unstructured":"Ryan, H. E., Lo, J. & Johnson, R. S. HIF-1\u03b1 is required for solid tumor formation and embryonic vascularization. EMBO J. 17, 3005\u20133015 (1998).","journal-title":"EMBO J."},{"key":"631_CR56","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/88842","volume":"28","author":"B Oosthuyse","year":"2001","unstructured":"Oosthuyse, B. et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28, 131\u2013138 (2001).","journal-title":"Nat. Genet."},{"key":"631_CR57","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/380439a0","volume":"380","author":"N Ferrara","year":"1996","unstructured":"Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439\u2013442 (1996).","journal-title":"Nature"},{"key":"631_CR58","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/380435a0","volume":"380","author":"P Carmeliet","year":"1996","unstructured":"Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435\u2013439 (1996).","journal-title":"Nature"},{"key":"631_CR59","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.devcel.2009.11.008","volume":"17","author":"SL Dunwoodie","year":"2009","unstructured":"Dunwoodie, S. L. The role of hypoxia in development of the mammalian embryo. Dev. Cell 17, 755\u2013773 (2009).","journal-title":"Dev. Cell"},{"key":"631_CR60","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/jcp.20525","volume":"206","author":"SA Vinores","year":"2006","unstructured":"Vinores, S. A. et al. Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J. Cell Physiol. 206, 749\u2013758 (2006).","journal-title":"J. Cell Physiol."},{"key":"631_CR61","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1158\/0008-5472.CAN-03-3017","volume":"64","author":"Y Mizukami","year":"2004","unstructured":"Mizukami, Y. et al. Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res. 64, 1765\u20131772 (2004).","journal-title":"Cancer Res."},{"key":"631_CR62","doi-asserted-by":"publisher","first-page":"13957","DOI":"10.1074\/jbc.M511763200","volume":"281","author":"Y Mizukami","year":"2006","unstructured":"Mizukami, Y. et al. Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase\/Rho\/ROCK and c-Myc. J. Biol. Chem. 281, 13957\u201313963 (2006).","journal-title":"J. Biol. Chem."},{"key":"631_CR63","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/35036374","volume":"2","author":"G Bergers","year":"2000","unstructured":"Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737\u2013744 (2000).","journal-title":"Nat. Cell Biol."},{"key":"631_CR64","doi-asserted-by":"publisher","first-page":"7806","DOI":"10.1128\/MCB.24.17.7806-7819.2004","volume":"24","author":"S Fujioka","year":"2004","unstructured":"Fujioka, S. et al. NF-\u03baB and AP-1 connection: mechanism of NF-\u03baB-dependent regulation of AP-1 activity. Mol. Cell Biol. 24, 7806\u20137819 (2004).","journal-title":"Mol. Cell Biol."},{"key":"631_CR65","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1101\/gad.1455706","volume":"20","author":"K Shchors","year":"2006","unstructured":"Shchors, K. et al. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1\u03b2. Genes Dev. 20, 2527\u20132538 (2006).","journal-title":"Genes Dev."},{"key":"631_CR66","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/nm1294","volume":"11","author":"Y Mizukami","year":"2005","unstructured":"Mizukami, Y. et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1\u03b1-deficient colon cancer cells. Nat. Med. 11, 992\u2013997 (2005).","journal-title":"Nat. Med."},{"key":"631_CR67","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/nature06613","volume":"451","author":"Z Arany","year":"2008","unstructured":"Arany, Z. et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1\u03b1. Nature 451, 1008\u20131012 (2008).","journal-title":"Nature"},{"key":"631_CR68","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cmet.2008.11.009","volume":"9","author":"Y Xue","year":"2009","unstructured":"Xue, Y. et al. Hypoxia-independent angiogenesis in adipose tissues during cold acclimation. Cell Metab. 9, 99\u2013109 (2009).","journal-title":"Cell Metab."},{"key":"631_CR69","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/oby.20206","volume":"21","author":"K Takahashi","year":"2013","unstructured":"Takahashi, K. et al. Endogenous oxidative stress, but not ER stress, induces hypoxia-independent VEGF120 release through PI3K-dependent pathways in 3T3-L1 adipocytes. Obesity 21, 1625\u20131634 (2013).","journal-title":"Obesity"},{"key":"631_CR70","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrm1911","volume":"7","author":"AK Olsson","year":"2006","unstructured":"Olsson, A. K., Dimberg, A., Kreuger, J. & Claesson-Welsh, L. VEGF receptor signalling \u2014 in control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359\u2013371 (2006).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"631_CR71","first-page":"519","volume":"8","author":"M Shibuya","year":"1990","unstructured":"Shibuya, M. et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene 8, 519\u2013527 (1990).","journal-title":"Oncogene"},{"key":"631_CR72","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1096\/fj.00-0383com","volume":"15","author":"K Iljin","year":"2001","unstructured":"Iljin, K. et al. VEGFR3 gene structure, regulatory region, and sequence polymorphisms. FASEB J. 15, 1028\u20131036 (2001).","journal-title":"FASEB J."},{"key":"631_CR73","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1050-1738(01)00140-2","volume":"12","author":"G Neufeld","year":"2002","unstructured":"Neufeld, G. et al. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc. Med. 12, 13\u201319 (2002).","journal-title":"Trends Cardiovasc. Med."},{"key":"631_CR74","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S0968-0004(03)00193-2","volume":"28","author":"MJ Cross","year":"2003","unstructured":"Cross, M. J., Dixelius, J., Matsumoto, T. & Claesson-Welsh, L. VEGF-receptor signal transduction. Trends Biochem. Sci. 28, 488\u2013494 (2003).","journal-title":"Trends Biochem. Sci."},{"key":"631_CR75","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1126\/science.1312256","volume":"255","author":"C de Vries","year":"1992","unstructured":"de Vries, C. et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989\u2013991 (1992).","journal-title":"Science"},{"key":"631_CR76","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1172\/JCI115568","volume":"89","author":"LB Jakeman","year":"1992","unstructured":"Jakeman, L. B., Winer, J., Bennett, G. L., Altar, C. A. & Ferrara, N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J. Clin. Invest. 89, 244\u2013253 (1992).","journal-title":"J. Clin. Invest."},{"key":"631_CR77","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1006\/bbrc.1997.7327","volume":"238","author":"A Sawano","year":"1997","unstructured":"Sawano, A., Takahashi, T., Yamaguchi, S. & Shibuya, M. The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLC\u03b3. Biochem. Biophys. Res. Commun. 238, 487\u2013491 (1997).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"631_CR78","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1074\/jbc.M506454200","volume":"281","author":"RD Meyer","year":"2006","unstructured":"Meyer, R. D., Mohammadi, M. & Rahimi, N. A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1\/FLT-1. J. Biol. Chem. 281, 867\u2013875 (2006).","journal-title":"J. Biol. Chem."},{"key":"631_CR79","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1093\/emboj\/19.15.4064","volume":"19","author":"H Gille","year":"2000","unstructured":"Gille, H. et al. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits VEGF-dependent PI 3 kinase activation and endothelial cell migration. EMBO J. 19, 4064\u20134073 (2000).","journal-title":"EMBO J."},{"key":"631_CR80","doi-asserted-by":"publisher","first-page":"25646","DOI":"10.1016\/S0021-9258(18)47298-5","volume":"269","author":"JE Park","year":"1994","unstructured":"Park, J. E., Chen, H. H., Winer, J., Houck, K. A. & Ferrara, N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1\/KDR. J. Biol. Chem. 269, 25646\u201325654 (1994).","journal-title":"J. Biol. Chem."},{"key":"631_CR81","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1002\/j.1460-2075.1996.tb00872.x","volume":"15","author":"T Davis-Smyth","year":"1996","unstructured":"Davis-Smyth, T., Chen, H., Park, J., Presta, L. G. & Ferrara, N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 15, 4919\u20134927 (1996).","journal-title":"EMBO J."},{"key":"631_CR82","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0092-8674(00)80456-0","volume":"91","author":"C Wiesmann","year":"1997","unstructured":"Wiesmann, C. et al. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 91, 695\u2013704 (1997).","journal-title":"Cell"},{"key":"631_CR83","doi-asserted-by":"publisher","first-page":"10382","DOI":"10.1074\/jbc.M313237200","volume":"279","author":"HW Christinger","year":"2004","unstructured":"Christinger, H. W., Fuh, G., de Vos, A. M. & Wiesmann, C. The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J. Biol. Chem. 279, 10382\u201310388 (2004).","journal-title":"J. Biol. Chem."},{"key":"631_CR84","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.str.2016.12.012","volume":"25","author":"S Markovic-Mueller","year":"2017","unstructured":"Markovic-Mueller, S. et al. Structure of the full-length VEGFR-1 extracellular domain in complex with VEGFA. Structure 25, 341\u2013352 (2017).","journal-title":"Structure"},{"key":"631_CR85","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10456-006-9055-8","volume":"9","author":"M Shibuya","year":"2006","unstructured":"Shibuya, M. Vascular endothelial growth factor receptor-1 (VEGFR-1\/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9, 225\u2013230 (2006).","journal-title":"Angiogenesis"},{"key":"631_CR86","doi-asserted-by":"publisher","first-page":"10705","DOI":"10.1073\/pnas.90.22.10705","volume":"90","author":"RL Kendall","year":"1993","unstructured":"Kendall, R. L. & Thomas, K. A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl Acad. Sci. USA 90, 10705\u201310709 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR87","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1172\/JCI17189","volume":"111","author":"SE Maynard","year":"2003","unstructured":"Maynard, S. E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649\u2013658 (2003).","journal-title":"J. Clin. Invest."},{"key":"631_CR88","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1056\/NEJMoa031884","volume":"350","author":"RJ Levine","year":"2004","unstructured":"Levine, R. J. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672\u2013683 (2004).","journal-title":"N. Engl. J. Med."},{"key":"631_CR89","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/376066a0","volume":"376","author":"GH Fong","year":"1995","unstructured":"Fong, G. H., Rossant, J., Gertsenstein, M. & Breitman, M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66\u201370 (1995).","journal-title":"Nature"},{"key":"631_CR90","doi-asserted-by":"publisher","first-page":"9349","DOI":"10.1073\/pnas.95.16.9349","volume":"95","author":"S Hiratsuka","year":"1998","unstructured":"Hiratsuka, S., Minowa, O., Kuno, J., Noda, T. & Shibuya, M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl Acad. Sci. USA 95, 9349\u20139354 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR91","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1182\/blood-2006-04-016030","volume":"108","author":"M Murakami","year":"2006","unstructured":"Murakami, M. et al. Signaling of vascular endothelial growth factor receptor- 1 tyrosine kinase promotes rheumatoid arthritis through activation of monocyte\/macrophages. Blood 108, 1849\u20131856 (2006).","journal-title":"Blood"},{"key":"631_CR92","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S1535-6108(02)00153-8","volume":"2","author":"S Hiratsuka","year":"2002","unstructured":"Hiratsuka, S. et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2, 289\u2013300 (2002).","journal-title":"Cancer Cell"},{"key":"631_CR93","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/ijc.21865","volume":"119","author":"Y Wu","year":"2006","unstructured":"Wu, Y. et al. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int. J. Cancer 119, 1519\u20131529 (2006).","journal-title":"Int. J. Cancer"},{"key":"631_CR94","doi-asserted-by":"publisher","first-page":"11590","DOI":"10.1073\/pnas.1109029108","volume":"108","author":"J Yao","year":"2011","unstructured":"Yao, J. et al. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PLGF antibodies efficacy. Proc. Natl Acad. Sci. USA 108, 11590\u201311595 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR95","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1126\/science.1079562","volume":"299","author":"J LeCouter","year":"2003","unstructured":"LeCouter, J. et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299, 890\u2013893 (2003).","journal-title":"Science"},{"key":"631_CR96","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/0006-291X(92)90483-2","volume":"187","author":"BI Terman","year":"1992","unstructured":"Terman, B. I. et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187, 1579\u20131586 (1992).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"631_CR97","doi-asserted-by":"publisher","first-page":"7533","DOI":"10.1073\/pnas.90.16.7533","volume":"90","author":"TP Quinn","year":"1993","unstructured":"Quinn, T. P., Peters, K. G., De Vries, C., Ferrara, N. & Williams, L. T. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc. Natl Acad. Sci. USA 90, 7533\u20137537 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR98","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.cell.2010.01.045","volume":"140","author":"T Tammela","year":"2010","unstructured":"Tammela, T. & Alitalo, K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 140, 460\u2013476 (2010).","journal-title":"Cell"},{"key":"631_CR99","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.yexcr.2005.11.012","volume":"312","author":"M Shibuya","year":"2005","unstructured":"Shibuya, M. & Claesson-Welsh, L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 312, 549\u2013560 (2005).","journal-title":"Exp. Cell Res."},{"key":"631_CR100","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/376062a0","volume":"376","author":"F Shalaby","year":"1995","unstructured":"Shalaby, F. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62\u201366 (1995).","journal-title":"Nature"},{"key":"631_CR101","doi-asserted-by":"publisher","first-page":"11197","DOI":"10.1074\/jbc.273.18.11197","volume":"273","author":"G Fuh","year":"1998","unstructured":"Fuh, G., Li, B., Crowley, C., Cunningham, B. & Wells, J. A. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J. Biol. Chem. 273, 11197\u201311204 (1998).","journal-title":"J. Biol. Chem."},{"key":"631_CR102","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nsmb1202","volume":"14","author":"C Ruch","year":"2007","unstructured":"Ruch, C., Skiniotis, G., Steinmetz, M. O., Walz, T. & Ballmer-Hofer, K. Structure of a VEGF-VEGF receptor complex determined by electron microscopy. Nat. Struct. Mol. Biol. 14, 249\u2013250 (2007).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"631_CR103","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1038\/sj.onc.1202527","volume":"18","author":"T Takahashi","year":"1999","unstructured":"Takahashi, T., Ueno, H. & Shibuya, M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18, 2221\u20132230 (1999).","journal-title":"Oncogene"},{"key":"631_CR104","doi-asserted-by":"publisher","first-page":"30336","DOI":"10.1074\/jbc.273.46.30336","volume":"273","author":"HP Gerber","year":"1998","unstructured":"Gerber, H. P. et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3\u2019-kinase\/Akt signal transduction pathway. Requirement for Flk-1\/KDR activation. J. Biol. Chem. 273, 30336\u201330343 (1998).","journal-title":"J. Biol. Chem."},{"key":"631_CR105","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1096\/fj.07-096438","volume":"22","author":"W Tan","year":"2008","unstructured":"Tan, W. et al. An essential role for Rac1 in endothelial cell function and vascular development. FASEB J. 22, 1829\u20131838 (2008).","journal-title":"FASEB J."},{"key":"631_CR106","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1073\/pnas.0404984102","volume":"102","author":"Y Sakurai","year":"2005","unstructured":"Sakurai, Y., Ohgimoto, K., Kataoka, Y., Yoshida, N. & Shibuya, M. Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc. Natl Acad. Sci. USA 102, 1076\u20131081 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR107","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1172\/JCI119006","volume":"98","author":"P Xia","year":"1996","unstructured":"Xia, P. et al. Characterization of vascular endothelial growth factor\u2019s effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. 98, 2018\u20132026 (1996).","journal-title":"J. Clin. Invest."},{"key":"631_CR108","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/emboj\/20.11.2768","volume":"20","author":"T Takahashi","year":"2001","unstructured":"Takahashi, T., Yamaguchi, S., Chida, K. & Shibuya, M. A single autophosphorylation site on KDR\/Flk-1 is essential for VEGF-A-dependent activation of PLC-\u03b3 and DNA synthesis in vascular endothelial cells. EMBO J. 20, 2768\u20132778 (2001).","journal-title":"EMBO J."},{"key":"631_CR109","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1073\/pnas.94.7.2999","volume":"94","author":"QS Ji","year":"1997","unstructured":"Ji, Q. S. et al. Essential role of the tyrosine kinase substrate phospholipase C-\u03b31 in mammalian growth and development. Proc. Natl Acad. Sci. USA 94, 2999\u20133003 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR110","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.devcel.2005.06.004","volume":"9","author":"G Jekely","year":"2005","unstructured":"Jekely, G., Sung, H. H., Luque, C. M. & Rorth, P. Regulators of endocytosis maintain localized receptor tyrosine kinase signaling in guided migration. Dev. Cell 9, 197\u2013207 (2005).","journal-title":"Dev. Cell"},{"key":"631_CR111","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1083\/jcb.200602080","volume":"174","author":"MG Lampugnani","year":"2006","unstructured":"Lampugnani, M. G., Orsenigo, F., Gagliani, M. C., Tacchetti, C. & Dejana, E. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J. Cell Biol. 174, 593\u2013604 (2006).","journal-title":"J. Cell Biol."},{"key":"631_CR112","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1182\/blood-2011-01-328773","volume":"118","author":"K Ballmer-Hofer","year":"2011","unstructured":"Ballmer-Hofer, K., Andersson, A. E., Ratcliffe, L. E. & Berger, P. Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output. Blood 118, 816\u2013826 (2011).","journal-title":"Blood"},{"key":"631_CR113","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/ncb2679","volume":"15","author":"M Nakayama","year":"2013","unstructured":"Nakayama, M. et al. Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nat. Cell Biol. 15, 249\u2013260 (2013).","journal-title":"Nat. Cell Biol."},{"key":"631_CR114","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature08995","volume":"465","author":"S Sawamiphak","year":"2010","unstructured":"Sawamiphak, S. et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465, 487\u2013491 (2010).","journal-title":"Nature"},{"key":"631_CR115","doi-asserted-by":"publisher","first-page":"eabn2611","DOI":"10.1126\/sciadv.abn2611","volume":"8","author":"JH Bae","year":"2022","unstructured":"Bae, J. H. et al. Gatekeeping role of Nf2\/Merlin in vascular tip EC induction through suppression of VEGFR2 internalization. Sci. Adv. 8, eabn2611 (2022).","journal-title":"Sci. Adv."},{"key":"631_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10359-x","volume":"10","author":"G Genet","year":"2019","unstructured":"Genet, G. et al. Endophilin-A2 dependent VEGFR2 endocytosis promotes sprouting angiogenesis. Nat. Commun. 10, 2350 (2019).","journal-title":"Nat. Commun."},{"key":"631_CR117","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1126\/science.282.5390.946","volume":"282","author":"DJ Dumont","year":"1998","unstructured":"Dumont, D. J. et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282, 946\u2013949 (1998).","journal-title":"Science"},{"key":"631_CR118","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/emboj\/20.6.1223","volume":"20","author":"T Veikkola","year":"2001","unstructured":"Veikkola, T. et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 20, 1223\u20131231 (2001).","journal-title":"EMBO J."},{"key":"631_CR119","doi-asserted-by":"publisher","first-page":"12960","DOI":"10.1073\/pnas.1301415110","volume":"110","author":"VM Leppanen","year":"2013","unstructured":"Leppanen, V. M. et al. Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. Proc. Natl Acad. Sci. USA 110, 12960\u201312965 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR120","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/84651","volume":"7","author":"T Makinen","year":"2001","unstructured":"Makinen, T. et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 7, 199\u2013205 (2001).","journal-title":"Nat. Med."},{"key":"631_CR121","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/jnci\/94.11.819","volume":"94","author":"Y He","year":"2002","unstructured":"He, Y. et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl Cancer Inst. 94, 819\u2013825 (2002).","journal-title":"J. Natl Cancer Inst."},{"key":"631_CR122","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2002-05-1329","volume":"101","author":"K Matsumura","year":"2003","unstructured":"Matsumura, K. et al. Modulation of VEGFR-2-mediated endothelial-cell activity by VEGF-C\/VEGFR-3. Blood 101, 1367\u20131374 (2003).","journal-title":"Blood"},{"key":"631_CR123","doi-asserted-by":"publisher","first-page":"5761","DOI":"10.1074\/jbc.271.10.5761","volume":"271","author":"S Soker","year":"1996","unstructured":"Soker, S., Fidder, H., Neufeld, G. & Klagsbrun, M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J. Biol. Chem. 271, 5761\u20135767 (1996).","journal-title":"J. Biol. Chem."},{"key":"631_CR124","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0092-8674(00)81402-6","volume":"92","author":"S Soker","year":"1998","unstructured":"Soker, S., Takashima, S., Miao, H. Q., Neufeld, G. & Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735\u2013745 (1998).","journal-title":"Cell"},{"key":"631_CR125","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1042\/BJ20071639","volume":"411","author":"C Pellet-Many","year":"2008","unstructured":"Pellet-Many, C., Frankel, P., Jia, H. & Zachary, I. Neuropilins: structure, function and role in disease. Biochem. J. 411, 211\u2013226 (2008).","journal-title":"Biochem. J."},{"key":"631_CR126","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1073\/pnas.0700043104","volume":"104","author":"CW Vander Kooi","year":"2007","unstructured":"Vander Kooi, C. W. et al. Structural basis for ligand and heparin binding to neuropilin B domains. Proc. Natl Acad. Sci. USA 104, 6152\u20136157 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR127","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1080\/19336918.2017.1372878","volume":"12","author":"S Sarabipour","year":"2018","unstructured":"Sarabipour, S. & Mac Gabhann, F. VEGF-A121a binding to Neuropilins \u2014 a concept revisited. Cell Adh. Migr. 12, 204\u2013214 (2018).","journal-title":"Cell Adh. Migr."},{"key":"631_CR128","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1042\/BST20140244","volume":"42","author":"A Lampropoulou","year":"2014","unstructured":"Lampropoulou, A. & Ruhrberg, C. Neuropilin regulation of angiogenesis. Biochem. Soc. Trans. 42, 1623\u20131628 (2014).","journal-title":"Biochem. Soc. Trans."},{"key":"631_CR129","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1083\/jcb.200903137","volume":"188","author":"Y Xu","year":"2010","unstructured":"Xu, Y. et al. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J. Cell Biol. 188, 115\u2013130 (2010).","journal-title":"J. Cell Biol."},{"key":"631_CR130","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ab.2018.10.001","volume":"564-565","author":"M Teran","year":"2019","unstructured":"Teran, M. & Nugent, M. A. Characterization of receptor binding kinetics for vascular endothelial growth factor-A using SPR. Anal. Biochem. 564-565, 21\u201331 (2019).","journal-title":"Anal. Biochem."},{"key":"631_CR131","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1242\/dev.103028","volume":"141","author":"A Fantin","year":"2014","unstructured":"Fantin, A. et al. Neuropilin 1 (NRP1) hypomorphism combined with defective VEGF-A binding reveals novel roles for NRP1 in developmental and pathological angiogenesis. Development 141, 556\u2013562 (2014).","journal-title":"Development"},{"key":"631_CR132","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S1050-1738(03)00105-1","volume":"13","author":"M Ema","year":"2003","unstructured":"Ema, M. & Rossant, J. Cell fate decisions in early blood vessel formation. Trends Cardiovasc. Med. 13, 254\u2013259 (2003).","journal-title":"Trends Cardiovasc. Med."},{"key":"631_CR133","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.devcel.2011.07.001","volume":"21","author":"A Armulik","year":"2011","unstructured":"Armulik, A., Genove, G. & Betsholtz, C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell 21, 193\u2013215 (2011).","journal-title":"Dev. Cell"},{"key":"631_CR134","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.trsl.2014.01.011","volume":"163","author":"A Geevarghese","year":"2014","unstructured":"Geevarghese, A. & Herman, I. M. Pericyte-endothelial crosstalk: implications and opportunities for advanced cellular therapies. Transl. Res. 163, 296\u2013306 (2014).","journal-title":"Transl. Res."},{"key":"631_CR135","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nm0603-685","volume":"9","author":"RK Jain","year":"2003","unstructured":"Jain, R. K. Molecular regulation of vessel maturation. Nat. Med. 9, 685\u2013693 (2003).","journal-title":"Nat. Med."},{"key":"631_CR136","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0092-8674(00)81436-1","volume":"93","author":"HU Wang","year":"1998","unstructured":"Wang, H. U., Chen, Z. F. & Anderson, D. J. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93, 741\u2013753 (1998).","journal-title":"Cell"},{"key":"631_CR137","doi-asserted-by":"publisher","first-page":"15949","DOI":"10.1073\/pnas.0407290101","volume":"101","author":"NW Gale","year":"2004","unstructured":"Gale, N. W. et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc. Natl Acad. Sci. USA 101, 15949\u201315954 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR138","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/ncb3555","volume":"19","author":"ME Pitulescu","year":"2017","unstructured":"Pitulescu, M. E. et al. Dll4 and Notch signalling couples sprouting angiogenesis and artery formation. Nat. Cell Biol. 19, 915\u2013927 (2017).","journal-title":"Nat. Cell Biol."},{"key":"631_CR139","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1161\/CIRCRESAHA.108.188805","volume":"104","author":"MR Swift","year":"2009","unstructured":"Swift, M. R. & Weinstein, B. M. Arterial-venous specification during development. Circ. Res. 104, 576\u2013588 (2009).","journal-title":"Circ. Res."},{"key":"631_CR140","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1182\/blood-2003-07-2315","volume":"103","author":"JB Kearney","year":"2004","unstructured":"Kearney, J. B., Kappas, N. C., Ellerstrom, C., DiPaola, F. W. & Bautch, V. L. The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. Blood 103, 4527\u20134535 (2004).","journal-title":"Blood"},{"key":"631_CR141","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.devcel.2009.07.011","volume":"17","author":"JC Chappell","year":"2009","unstructured":"Chappell, J. C., Taylor, S. M., Ferrara, N. & Bautch, V. L. Local guidance of emerging vessel sprouts requires soluble Flt-1. Dev. Cell 17, 377\u2013386 (2009).","journal-title":"Dev. Cell"},{"key":"631_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01738-3","volume":"8","author":"HM Eilken","year":"2017","unstructured":"Eilken, H. M. et al. Pericytes regulate VEGF-induced endothelial sprouting through VEGFR1. Nat. Commun. 8, 1574 (2017).","journal-title":"Nat. Commun."},{"key":"631_CR143","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1083\/jcb.200302047","volume":"161","author":"H Gerhardt","year":"2003","unstructured":"Gerhardt, H. et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161, 1163\u20131177 (2003).","journal-title":"J. Cell Biol."},{"key":"631_CR144","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1242\/dev.062323","volume":"138","author":"I Geudens","year":"2011","unstructured":"Geudens, I. & Gerhardt, H. Coordinating cell behaviour during blood vessel formation. Development 138, 4569\u20134583 (2011).","journal-title":"Development"},{"key":"631_CR145","doi-asserted-by":"publisher","first-page":"7243","DOI":"10.1158\/1078-0432.CCR-07-1393","volume":"13","author":"M Yan","year":"2007","unstructured":"Yan, M. & Plowman, G. D. Delta-like 4\/Notch signaling and its therapeutic implications. Clin. Cancer Res. 13, 7243\u20137246 (2007).","journal-title":"Clin. Cancer Res."},{"key":"631_CR146","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298\u2013307 (2011).","journal-title":"Nature"},{"key":"631_CR147","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.cell.2007.06.054","volume":"130","author":"S Lee","year":"2007","unstructured":"Lee, S. et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130, 691\u2013703 (2007).","journal-title":"Cell"},{"key":"631_CR148","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nm0398-336","volume":"4","author":"N Ferrara","year":"1998","unstructured":"Ferrara, N. et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. 4, 336\u2013340 (1998).","journal-title":"Nat. Med."},{"key":"631_CR149","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/emmm.201302618","volume":"5","author":"M Kim","year":"2013","unstructured":"Kim, M. et al. VEGF-A regulated by progesterone governs uterine angiogenesis and vascular remodelling during pregnancy. EMBO Mol. Med. 5, 1415\u20131430\u00a0(2013).","journal-title":"EMBO Mol. Med."},{"key":"631_CR150","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166658","volume":"11","author":"S Liu","year":"2016","unstructured":"Liu, S. et al. Efficacy of anti-VEGF\/VEGFR agents on animal models of endometriosis: a systematic review and meta-analysis. PLoS ONE\u00a011, e0166658 (2016).","journal-title":"PLoS ONE"},{"key":"631_CR151","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/35091000","volume":"412","author":"J LeCouter","year":"2001","unstructured":"LeCouter, J. et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 412, 877\u2013884 (2001).","journal-title":"Nature"},{"key":"631_CR152","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/S0002-9440(10)64322-2","volume":"162","author":"N Ferrara","year":"2003","unstructured":"Ferrara, N. et al. Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. Am. J. Pathol. 162, 1881\u20131893 (2003).","journal-title":"Am. J. Pathol."},{"key":"631_CR153","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(00)03577-7","volume":"357","author":"JM Roberts","year":"2001","unstructured":"Roberts, J. M. & Cooper, D. W. Pathogenesis and genetics of pre-eclampsia. Lancet 357, 53\u201356 (2001).","journal-title":"Lancet"},{"key":"631_CR154","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1414838","volume":"374","author":"H Zeisler","year":"2016","unstructured":"Zeisler, H. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N. Engl. J. Med. 374, 13\u201322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"631_CR155","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1681\/ASN.2015020157","volume":"27","author":"R Thadhani","year":"2016","unstructured":"Thadhani, R. et al. Removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J. Am. Soc. Nephrol. 27, 903\u2013913 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"631_CR156","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1161\/HYPERTENSIONAHA.116.07286","volume":"67","author":"A Makris","year":"2016","unstructured":"Makris, A. et al. Placental growth factor reduces blood pressure in a uteroplacental ischemia model of preeclampsia in nonhuman primates. Hypertension 67, 1263\u20131272 (2016).","journal-title":"Hypertension"},{"key":"631_CR157","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/nbt.4297","volume":"36","author":"AA Turanov","year":"2018","unstructured":"Turanov, A. A. et al. RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat. Biotechnol. 36, 1164\u20131173 (2018).","journal-title":"Nat. Biotechnol."},{"key":"631_CR158","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcdb.2021.06.025","volume":"123","author":"C Owen-Woods","year":"2022","unstructured":"Owen-Woods, C. & Kusumbe, A. Fundamentals of bone vasculature: specialization, interactions and functions. Semin. Cell Dev. Biol. 123, 36\u201347 (2022).","journal-title":"Semin. Cell Dev. Biol."},{"key":"631_CR159","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/9467","volume":"5","author":"HP Gerber","year":"1999","unstructured":"Gerber, H. P. et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5, 623\u2013628 (1999).","journal-title":"Nat. Med."},{"key":"631_CR160","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature13145","volume":"507","author":"AP Kusumbe","year":"2014","unstructured":"Kusumbe, A. P., Ramasamy, S. K. & Adams, R. H. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature 507, 323\u2013328 (2014).","journal-title":"Nature"},{"key":"631_CR161","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1242\/dev.136861","volume":"143","author":"KK Sivaraj","year":"2016","unstructured":"Sivaraj, K. K. & Adams, R. H. Blood vessel formation and function in bone. Development 143, 2706\u20132715 (2016).","journal-title":"Development"},{"key":"631_CR162","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0925-4773(01)00601-3","volume":"111","author":"C Maes","year":"2002","unstructured":"Maes, C. et al. Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech. Dev. 111, 61\u201373 (2002).","journal-title":"Mech. Dev."},{"key":"631_CR163","doi-asserted-by":"publisher","first-page":"9656","DOI":"10.1073\/pnas.152324099","volume":"99","author":"J Street","year":"2002","unstructured":"Street, J. et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc. Natl Acad. Sci. USA 99, 9656\u20139661 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR164","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1634\/stemcells.19-2-99","volume":"19","author":"A Janowska-Wieczorek","year":"2001","unstructured":"Janowska-Wieczorek, A., Majka, M., Ratajczak, J. & Ratajczak, M. Z. Autocrine\/paracrine mechanisms in human hematopoiesis. Stem Cell 19, 99\u2013107 (2001).","journal-title":"Stem Cell"},{"key":"631_CR165","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1242\/dev.124.10.2039","volume":"124","author":"N Kabrun","year":"1997","unstructured":"Kabrun, N. et al. Flk-1 expression defines a population of early embryonic hematopoietic precursors. Development 124, 2039\u20132048 (1997).","journal-title":"Development"},{"key":"631_CR166","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/nature00821","volume":"417","author":"H-P Gerber","year":"2002","unstructured":"Gerber, H.-P. et al. VEGF regulates hematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417, 954\u2013958 (2002).","journal-title":"Nature"},{"key":"631_CR167","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/nm740","volume":"8","author":"K Hattori","year":"2002","unstructured":"Hattori, K. et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment. Nat. Med. 8, 841\u2013849 (2002).","journal-title":"Nat. Med."},{"key":"631_CR168","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00109-002-0397-4","volume":"81","author":"HP Gerber","year":"2003","unstructured":"Gerber, H. P. & Ferrara, N. The role of VEGF in normal and neoplastic hematopoiesis. J. Mol. Med. 81, 20\u201331 (2003).","journal-title":"J. Mol. Med."},{"key":"631_CR169","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1182\/blood.V92.11.4150","volume":"92","author":"D Gabrilovich","year":"1998","unstructured":"Gabrilovich, D. et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92, 4150\u20134166 (1998).","journal-title":"Blood"},{"key":"631_CR170","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374\u2013403 (2023).","journal-title":"Cancer Cell"},{"key":"631_CR171","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/nm.3291","volume":"19","author":"AS Chung","year":"2013","unstructured":"Chung, A. S. et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med. 19, 1114\u20131123 (2013).","journal-title":"Nat. Med."},{"key":"631_CR172","doi-asserted-by":"publisher","first-page":"21598","DOI":"10.1073\/pnas.2008112117","volume":"117","author":"Y Itatani","year":"2020","unstructured":"Itatani, Y. et al. Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer. Proc. Natl Acad. Sci. USA 117, 21598\u201321608 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR173","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"631_CR174","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41577-022-00694-4","volume":"22","author":"J Amersfoort","year":"2022","unstructured":"Amersfoort, J., Eelen, G. & Carmeliet, P. Immunomodulation by endothelial cells \u2014 partnering up with the immune system? Nat. Rev. Immunol. 22, 576\u2013588 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"631_CR175","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.gde.2004.12.005","volume":"15","author":"P Baluk","year":"2005","unstructured":"Baluk, P., Hashizume, H. & McDonald, D. M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 15, 102\u2013111 (2005).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"631_CR176","first-page":"4264","volume":"56","author":"Y Boucher","year":"1996","unstructured":"Boucher, Y., Leunig, M. & Jain, R. K. Tumor angiogenesis and interstitial hypertension. Cancer Res. 56, 4264\u20134266 (1996).","journal-title":"Cancer Res."},{"key":"631_CR177","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/nbt1323","volume":"25","author":"F Shojaei","year":"2007","unstructured":"Shojaei, F. et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 25, 911\u2013920 (2007).","journal-title":"Nat. Biotechnol."},{"key":"631_CR178","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1158\/2326-6066.CIR-15-0313","volume":"4","author":"W Liang","year":"2016","unstructured":"Liang, W. & Ferrara, N. The complex role of neutrophils in tumor angiogenesis and metastasis. Cancer Immunol. Res. 4, 83\u201391 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"631_CR179","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/nature06348","volume":"450","author":"F Shojaei","year":"2007","unstructured":"Shojaei, F. et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450, 825\u2013831 (2007).","journal-title":"Nature"},{"key":"631_CR180","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1152\/physrev.00012.2017","volume":"98","author":"L Negri","year":"2018","unstructured":"Negri, L. & Ferrara, N. The prokineticins: neuromodulators and mediators of inflammation and myeloid cell-dependent angiogenesis. Physiol. Rev. 98, 1055\u20131082 (2018).","journal-title":"Physiol. Rev."},{"key":"631_CR181","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich, D. I. Myeloid-derived suppressor cells. Cancer Immunol. Res. 5, 3\u20138 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"631_CR182","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41577-022-00737-w","volume":"23","author":"S Goswami","year":"2023","unstructured":"Goswami, S., Anandhan, S., Raychaudhuri, D. & Sharma, P. Myeloid cell-targeted therapies for solid tumours. Nat. Rev. Immunol. 23, 106\u2013120 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"631_CR183","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.cell.2005.02.034","volume":"121","author":"A Orimo","year":"2005","unstructured":"Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\/CXCL12 secretion. Cell 121, 335\u2013348 (2005).","journal-title":"Cell"},{"key":"631_CR184","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccr.2008.12.004","volume":"15","author":"Y Crawford","year":"2009","unstructured":"Crawford, Y. et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15, 21\u201334 (2009).","journal-title":"Cancer Cell"},{"key":"631_CR185","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10456-019-09684-y","volume":"23","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y., Wang, S. & Dudley, A. C. Models and molecular mechanisms of blood vessel co-option by cancer cells. Angiogenesis 23, 17\u201325 (2020).","journal-title":"Angiogenesis"},{"key":"631_CR186","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc1092","volume":"3","author":"MJ Hendrix","year":"2003","unstructured":"Hendrix, M. J., Seftor, E. A., Hess, A. R. & Seftor, R. E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer 3, 411\u2013421 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"631_CR187","doi-asserted-by":"publisher","first-page":"100954","DOI":"10.1016\/j.preteyeres.2021.100954","volume":"84","author":"A Uemura","year":"2021","unstructured":"Uemura, A. et al. VEGFR1 signaling in retinal angiogenesis and microinflammation. Prog. Retin. Eye Res. 84, 100954\u00a0(2021).","journal-title":"Prog. Retin. Eye Res."},{"key":"631_CR188","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/nature04482","volume":"438","author":"RF Gariano","year":"2005","unstructured":"Gariano, R. F. & Gardner, T. W. Retinal angiogenesis in development and disease. Nature 438, 960\u2013966 (2005).","journal-title":"Nature"},{"key":"631_CR189","doi-asserted-by":"publisher","first-page":"796143","DOI":"10.3389\/fped.2021.796143","volume":"9","author":"A Ramshekar","year":"2021","unstructured":"Ramshekar, A. & Hartnett, M. E. Vascular endothelial growth factor signaling in models of oxygen-induced retinopathy: insights into mechanisms of pathology in retinopathy of prematurity. Front. Pediatr. 9, 796143 (2021).","journal-title":"Front. Pediatr."},{"key":"631_CR190","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","volume":"382","author":"A Hellstrom","year":"2013","unstructured":"Hellstrom, A., Smith, L. E. & Dammann, O. Retinopathy of prematurity. Lancet 382, 1445\u20131457 (2013).","journal-title":"Lancet"},{"key":"631_CR191","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello, L. P. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331, 1480\u20131487 (1994).","journal-title":"N. Engl. J. Med."},{"key":"631_CR192","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0002-9394(14)75794-0","volume":"118","author":"AP Adamis","year":"1994","unstructured":"Adamis, A. P. et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118, 445\u2013450 (1994).","journal-title":"Am. J. Ophthalmol."},{"key":"631_CR193","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0002-9440(10)61231-X","volume":"167","author":"AG Marneros","year":"2005","unstructured":"Marneros, A. G. et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am. J. Pathol. 167, 1451\u20131459 (2005).","journal-title":"Am. J. Pathol."},{"key":"631_CR194","doi-asserted-by":"publisher","first-page":"18751","DOI":"10.1073\/pnas.0905010106","volume":"106","author":"M Saint-Geniez","year":"2009","unstructured":"Saint-Geniez, M., Kurihara, T., Sekiyama, E., Maldonado, A. E. & D\u2019Amore, P. A. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc. Natl Acad. Sci. USA 106, 18751\u201318756 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR195","doi-asserted-by":"publisher","first-page":"pgac166","DOI":"10.1093\/pnasnexus\/pgac166","volume":"1","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Vascular endothelial growth factor from retinal pigment epithelium is essential in choriocapillaris and axial length maintenance. PNAS Nexus 1, pgac166 (2022).","journal-title":"PNAS Nexus"},{"key":"631_CR196","doi-asserted-by":"publisher","first-page":"100997","DOI":"10.1016\/j.preteyeres.2021.100997","volume":"87","author":"R Lejoyeux","year":"2022","unstructured":"Lejoyeux, R. et al. Choriocapillaris: fundamentals and advancements. Prog. Retin. Eye Res. 87, 100997 (2022).","journal-title":"Prog. Retin. Eye Res."},{"key":"631_CR197","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/nm1010-1107","volume":"16","author":"N Ferrara","year":"2010","unstructured":"Ferrara, N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat. Med. 16, 1107\u20131111 (2010).","journal-title":"Nat. Med."},{"key":"631_CR198","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1056\/NEJMra0801537","volume":"358","author":"RD Jager","year":"2008","unstructured":"Jager, R. D., Mieler, W. F. & Miller, J. W. Age-related macular degeneration. N. Engl. J. Med. 358, 2606\u20132617 (2008).","journal-title":"N. Engl. J. Med."},{"key":"631_CR199","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.2174\/1389450122999210128180725","volume":"22","author":"L Toto","year":"2021","unstructured":"Toto, L., Di Antonio, L., Costantino, O. & Mastropasqua, R. Anti-VEGF therapy in myopic CNV. Curr. Drug Targets 22, 1054\u20131063 (2021).","journal-title":"Curr. Drug Targets"},{"key":"631_CR200","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier, J. S. et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399, 729\u2013740 (2022).","journal-title":"Lancet"},{"key":"631_CR201","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3109\/03009734.2015.1064501","volume":"120","author":"L Claesson-Welsh","year":"2015","unstructured":"Claesson-Welsh, L. Vascular permeability \u2014 the essentials. Ups. J. Med. Sci. 120, 135\u2013143 (2015).","journal-title":"Ups. J. Med. Sci."},{"key":"631_CR202","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.3390\/ijms23073645","volume":"23","author":"JL Wautier","year":"2022","unstructured":"Wautier, J. L. & Wautier, M. P. Vascular permeability in diseases. Int. J. Mol. Sci.\u00a023,\u00a03645\u00a0(2022).","journal-title":"Int. J. Mol. Sci."},{"key":"631_CR203","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/sj.bjc.6604929","volume":"100","author":"JA Nagy","year":"2009","unstructured":"Nagy, J. A., Chang, S. H., Dvorak, A. M. & Dvorak, H. F. Why are tumour blood vessels abnormal and why is it important to know? Br. J. Cancer 100, 865\u2013869 (2009).","journal-title":"Br. J. Cancer"},{"key":"631_CR204","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1126\/science.6823562","volume":"219","author":"DR Senger","year":"1983","unstructured":"Senger, D. R. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983\u2013985 (1983).","journal-title":"Science"},{"key":"631_CR205","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1055\/s-0039-1687908","volume":"45","author":"HF Dvorak","year":"2019","unstructured":"Dvorak, H. F. Tumors: wounds that do not heal-A historical perspective with a focus on the fundamental roles of increased vascular permeability and clotting. Semin. Thromb. Hemost. 45, 576\u2013592 (2019).","journal-title":"Semin. Thromb. Hemost."},{"key":"631_CR206","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/S1097-2765(00)80221-X","volume":"4","author":"BP Eliceiri","year":"1999","unstructured":"Eliceiri, B. P. et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 4, 915\u2013924 (1999).","journal-title":"Mol. Cell"},{"key":"631_CR207","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11017","volume":"7","author":"X Li","year":"2016","unstructured":"Li, X. et al. VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread. Nat. Commun. 7, 11017 (2016).","journal-title":"Nat. Commun."},{"key":"631_CR208","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1084\/jem.20111343","volume":"209","author":"Z Sun","year":"2012","unstructured":"Sun, Z. et al. VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd. J. Exp. Med. 209, 1363\u20131377 (2012).","journal-title":"J. Exp. Med."},{"key":"631_CR209","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1083\/jcb.200408130","volume":"167","author":"S Weis","year":"2004","unstructured":"Weis, S., Cui, J., Barnes, L. & Cheresh, D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J. Cell Biol. 167, 223\u2013229 (2004).","journal-title":"J. Cell Biol."},{"key":"631_CR210","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.devcel.2011.11.002","volume":"22","author":"XL Chen","year":"2012","unstructured":"Chen, X. L. et al. VEGF-induced vascular permeability is mediated by FAK. Dev. Cell 22, 146\u2013157 (2012).","journal-title":"Dev. Cell"},{"key":"631_CR211","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.54056","volume":"9","author":"RO Smith","year":"2020","unstructured":"Smith, R. O. et al. Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin. eLife 9, e54056\u00a0(2020).","journal-title":"eLife"},{"key":"631_CR212","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1083\/jcb.144.3.575","volume":"144","author":"IM Ethell","year":"1999","unstructured":"Ethell, I. M. & Yamaguchi, Y. Cell surface heparan sulfate proteoglycan syndecan-2 induces the maturation of dendritic spines in rat hippocampal neurons. J. Cell Biol. 144, 575\u2013586 (1999).","journal-title":"J. Cell Biol."},{"key":"631_CR213","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood.2020010447","volume":"139","author":"CM Termini","year":"2022","unstructured":"Termini, C. M. et al. Syndecan-2 enriches for hematopoietic stem cells and regulates stem cell repopulating capacity. Blood 139, 188\u2013204 (2022).","journal-title":"Blood"},{"key":"631_CR214","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1182\/blood-2003-06-1783","volume":"103","author":"E Chen","year":"2004","unstructured":"Chen, E., Hermanson, S. & Ekker, S. C. Syndecan-2 is essential for angiogenic sprouting during zebrafish development. Blood 103, 1710\u20131719 (2004).","journal-title":"Blood"},{"key":"631_CR215","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/s44161-022-00064-2","volume":"1","author":"F Corti","year":"2022","unstructured":"Corti, F. et al. Syndecan-2 selectively regulates VEGF-induced vascular permeability. Nat. Cardiovasc. Res. 1, 518\u2013528 (2022).","journal-title":"Nat. Cardiovasc. Res."},{"key":"631_CR216","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1172\/JCI8218","volume":"104","author":"N van Bruggen","year":"1999","unstructured":"van Bruggen, N. et al. VEGF antagonism reduces edema formation and tissue damage after ischemia\/reperfusion injury in the mouse brain. J. Clin. Invest. 104, 1613\u20131620 (1999).","journal-title":"J. Clin. Invest."},{"key":"631_CR217","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash, J. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA 99, 11393\u201311398 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR218","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1167\/iovs.07-1194","volume":"49","author":"C Campa","year":"2008","unstructured":"Campa, C. et al. Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes. Invest. Ophthalmol. Vis. Sci. 49, 1178\u20131183 (2008).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"631_CR219","first-page":"3158","volume":"41","author":"N Kwak","year":"2000","unstructured":"Kwak, N., Okamoto, N., Wood, J. M. & Campochiaro, P. A. VEGF is major stimulator in model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 41, 3158\u20133164 (2000).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"631_CR220","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2337\/diab.46.9.1473","volume":"46","author":"LP Aiello","year":"1997","unstructured":"Aiello, L. P. et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective \u03b2-isoform-selective inhibitor. Diabetes 46, 1473\u20131480 (1997).","journal-title":"Diabetes"},{"key":"631_CR221","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/labinvest.3700436","volume":"86","author":"JA Nagy","year":"2006","unstructured":"Nagy, J. A. et al. Permeability properties of tumor surrogate blood vessels induced by VEGF-A. Lab. Invest. 86, 767\u2013780 (2006).","journal-title":"Lab. Invest."},{"key":"631_CR222","doi-asserted-by":"publisher","first-page":"14765","DOI":"10.1073\/pnas.93.25.14765","volume":"93","author":"F Yuan","year":"1996","unstructured":"Yuan, F. et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor\/vascular permeability factor antibody. Proc. Natl Acad. Sci. USA 93, 14765\u201314770 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR223","doi-asserted-by":"publisher","first-page":"14452","DOI":"10.1073\/pnas.1508520112","volume":"112","author":"AS Mao","year":"2015","unstructured":"Mao, A. S. & Mooney, D. J. Regenerative medicine: current therapies and future directions. Proc. Natl Acad. Sci. USA 112, 14452\u201314459 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR224","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/70928","volume":"5","author":"N Ferrara","year":"1999","unstructured":"Ferrara, N. & Alitalo, K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 5, 1359\u20131364 (1999).","journal-title":"Nat. Med."},{"key":"631_CR225","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jss.2008.04.023","volume":"153","author":"P Bao","year":"2009","unstructured":"Bao, P. et al. The role of vascular endothelial growth factor in wound healing. J. Surg. Res. 153, 347\u2013358 (2009).","journal-title":"J. Surg. Res."},{"key":"631_CR226","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S0008-6363(98)00136-9","volume":"40","author":"JJ Lopez","year":"1998","unstructured":"Lopez, J. J. et al. VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc. Res. 40, 272\u2013281 (1998).","journal-title":"Cardiovasc. Res."},{"key":"631_CR227","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/nm1095-1085","volume":"1","author":"JD Pearlman","year":"1995","unstructured":"Pearlman, J. D. et al. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat. Med. 1, 1085\u20131089 (1995).","journal-title":"Nat. Med."},{"key":"631_CR228","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1161\/01.CIR.0000061911.47710.8A","volume":"107","author":"TD Henry","year":"2003","unstructured":"Henry, T. D. et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107, 1359\u20131365 (2003).","journal-title":"Circulation"},{"key":"631_CR229","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature04483","volume":"438","author":"N Ferrara","year":"2005","unstructured":"Ferrara, N. & Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967\u2013974 (2005).","journal-title":"Nature"},{"key":"631_CR230","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMc071536","volume":"357","author":"N L\u2019Heureux","year":"2007","unstructured":"L\u2019Heureux, N., McAllister, T. N. & de la Fuente, L. M. Tissue-engineered blood vessel for adult arterial revascularization. N. Engl. J. Med. 357, 1451\u20131453 (2007).","journal-title":"N. Engl. J. Med."},{"key":"631_CR231","doi-asserted-by":"publisher","first-page":"7432","DOI":"10.1016\/j.biomaterials.2011.06.027","volume":"32","author":"SM Anderson","year":"2011","unstructured":"Anderson, S. M., Siegman, S. N. & Segura, T. The effect of vascular endothelial growth factor (VEGF) presentation within fibrin matrices on endothelial cell branching. Biomaterials 32, 7432\u20137443 (2011).","journal-title":"Biomaterials"},{"key":"631_CR232","doi-asserted-by":"publisher","first-page":"H455","DOI":"10.1152\/ajpheart.00726.2015","volume":"310","author":"L Hou","year":"2016","unstructured":"Hou, L., Kim, J. J., Woo, Y. J. & Huang, N. F. Stem cell-based therapies to promote angiogenesis in ischemic cardiovascular disease. Am. J. Physiol. Heart Circ. Physiol. 310, H455\u2013H465 (2016).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"631_CR233","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1161\/CIRCULATIONAHA.109.881441","volume":"122","author":"NJ Leeper","year":"2010","unstructured":"Leeper, N. J., Hunter, A. L. & Cooke, J. P. Stem cell therapy for vascular regeneration: adult, embryonic, and induced pluripotent stem cells. Circulation 122, 517\u2013526 (2010).","journal-title":"Circulation"},{"key":"631_CR234","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrm2199","volume":"8","author":"D Ron","year":"2007","unstructured":"Ron, D. & Walter, P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8, 519\u2013529 (2007).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"631_CR235","doi-asserted-by":"publisher","first-page":"eaat5314","DOI":"10.1126\/science.aat5314","volume":"368","author":"M Costa-Mattioli","year":"2020","unstructured":"Costa-Mattioli, M. & Walter, P. The integrated stress response: from mechanism to disease. Science 368, eaat5314 (2020).","journal-title":"Science"},{"key":"631_CR236","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1172\/JCI200521848","volume":"115","author":"K Zhang","year":"2005","unstructured":"Zhang, K. et al. The unfolded protein response sensor IRE1\u03b1 is required at 2 distinct steps in B cell lymphopoiesis. J. Clin. Invest. 115, 268\u2013281 (2005).","journal-title":"J. Clin. Invest."},{"key":"631_CR237","doi-asserted-by":"publisher","first-page":"16657","DOI":"10.1073\/pnas.0903775106","volume":"106","author":"T Iwawaki","year":"2009","unstructured":"Iwawaki, T., Akai, R., Yamanaka, S. & Kohno, K. Function of IRE1 alpha in the placenta is essential for placental development and embryonic viability. Proc. Natl Acad. Sci. USA 106, 16657\u201316662 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR238","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.molcel.2014.03.022","volume":"54","author":"E Karali","year":"2014","unstructured":"Karali, E. et al. VEGF Signals through ATF6 and PERK to promote endothelial cell survival and angiogenesis in the absence of ER stress. Mol. Cell 54, 559\u2013572 (2014).","journal-title":"Mol. Cell"},{"key":"631_CR239","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1161\/CIRCULATIONAHA.111.041830","volume":"125","author":"C Loinard","year":"2012","unstructured":"Loinard, C. et al. C\/EBP homologous protein-10 (CHOP-10) limits postnatal neovascularization through control of endothelial nitric oxide synthase gene expression. Circulation 125, 1014\u20131026 (2012).","journal-title":"Circulation"},{"key":"631_CR240","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20108-0","volume":"11","author":"C Zhong","year":"2020","unstructured":"Zhong, C. et al. Inhibition of protein glycosylation is a novel pro-angiogenic strategy that acts via activation of stress pathways. Nat. Commun. 11, 6330 (2020).","journal-title":"Nat. Commun."},{"key":"631_CR241","doi-asserted-by":"publisher","first-page":"723","DOI":"10.4161\/cbt.5.7.2967","volume":"5","author":"DR Fels","year":"2006","unstructured":"Fels, D. R. & Koumenis, C. The PERK\/eIF2\u03b1\/ATF4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biol. Ther. 5, 723\u2013728 (2006).","journal-title":"Cancer Biol. Ther."},{"key":"631_CR242","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.ajpath.2012.12.020","volume":"182","author":"L Liu","year":"2013","unstructured":"Liu, L. et al. Targeting the IRE1\u03b1\/XBP1 and ATF6 arms of the unfolded protein response enhances VEGF blockade to prevent retinal and choroidal neovascularization. Am. J. Pathol. 182, 1412\u20131424 (2013).","journal-title":"Am. J. Pathol."},{"key":"631_CR243","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1161\/01.CIR.99.1.111","volume":"99","author":"A Rivard","year":"1999","unstructured":"Rivard, A. et al. Age-dependent impairment of angiogenesis. Circulation 99, 111\u2013120 (1999).","journal-title":"Circulation"},{"key":"631_CR244","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.bbadis.2018.08.008","volume":"1865","author":"G Jia","year":"2019","unstructured":"Jia, G., Aroor, A. R., Jia, C. & Sowers, J. R. Endothelial cell senescence in aging-related vascular dysfunction. Biochim. Biophys. Acta Mol. Basis Dis. 1865, 1802\u20131809 (2019).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"631_CR245","doi-asserted-by":"publisher","first-page":"17018","DOI":"10.1073\/pnas.0607873103","volume":"103","author":"T Hayashi","year":"2006","unstructured":"Hayashi, T. et al. Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. Proc. Natl Acad. Sci. USA 103, 17018\u201317023 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR246","doi-asserted-by":"publisher","first-page":"H1829","DOI":"10.1152\/ajpheart.00230.2009","volume":"297","author":"YM Yang","year":"2009","unstructured":"Yang, Y. M., Huang, A., Kaley, G. & Sun, D. eNOS uncoupling and endothelial dysfunction in aged vessels. Am. J. Physiol. Heart Circ. Physiol. 297, H1829\u2013H1836 (2009).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"631_CR247","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1161\/CIRCULATIONAHA.109.909218","volume":"122","author":"XW Cheng","year":"2010","unstructured":"Cheng, X. W. et al. Exercise training stimulates ischemia-induced neovascularization via phosphatidylinositol 3-kinase\/Akt-dependent hypoxia-induced factor-1\u03b1 reactivation in mice of advanced age. Circulation 122, 707\u2013716 (2010).","journal-title":"Circulation"},{"key":"631_CR248","doi-asserted-by":"publisher","first-page":"abc8579","DOI":"10.1126\/science.abc8479","volume":"373","author":"M Grunewald","year":"2021","unstructured":"Grunewald, M. et al. Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span. Science 373, abc8579 (2021).","journal-title":"Science"},{"key":"631_CR249","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1126\/science.abj8674","volume":"373","author":"HG Augustin","year":"2021","unstructured":"Augustin, H. G. & Kipnis, J. Vascular rejuvenation is geroprotective. Science 373, 490\u2013491 (2021).","journal-title":"Science"},{"key":"631_CR250","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1096\/fj.201700761RR","volume":"32","author":"AG Marneros","year":"2018","unstructured":"Marneros, A. G. Effects of chronically increased VEGF-A on the aging heart. FASEB J. 32, 1550\u20131565 (2018).","journal-title":"FASEB J."},{"key":"631_CR251","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1242\/dev.126.6.1149","volume":"126","author":"HP Gerber","year":"1999","unstructured":"Gerber, H. P. et al. VEGF is required for growth and survival in neonatal mice. Development 126, 1149\u20131159 (1999).","journal-title":"Development"},{"key":"631_CR252","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1172\/JCI35298","volume":"118","author":"M Murakami","year":"2008","unstructured":"Murakami, M. et al. The FGF system has a key role in regulating vascular integrity. J. Clin. Invest. 118, 3355\u20133366 (2008).","journal-title":"J. Clin. Invest."},{"key":"631_CR253","doi-asserted-by":"publisher","first-page":"13379","DOI":"10.1073\/pnas.1324235111","volume":"111","author":"SS Oladipupo","year":"2014","unstructured":"Oladipupo, S. S. et al. Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proc. Natl Acad. Sci. USA 111, 13379\u201313384 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR254","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20212539","volume":"219","author":"P Li","year":"2022","unstructured":"Li, P. & Ferrara, N. Vascular heterogeneity: VEGF receptors make blood vessels special. J. Exp. Med. 219, e20212539\u00a0(2022).","journal-title":"J. Exp. Med."},{"key":"631_CR255","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20210565","volume":"219","author":"S Karaman","year":"2022","unstructured":"Karaman, S. et al. Interplay of vascular endothelial growth factor receptors in organ-specific vessel maintenance. J. Exp. Med. 219, e20210565\u00a0(2022).","journal-title":"J. Exp. Med."},{"key":"631_CR256","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.omtm.2021.03.013","volume":"21","author":"J Bosco","year":"2021","unstructured":"Bosco, J. et al. VEGFR-1\/Flt-1 inhibition increases angiogenesis and improves muscle function in a mouse model of Duchenne muscular dystrophy. Mol. Ther. Methods Clin. Dev. 21, 369\u2013381 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"631_CR257","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"631_CR258","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","volume":"15","author":"KA Khan","year":"2018","unstructured":"Khan, K. A. & Kerbel, R. S. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat. Rev. Clin. Oncol. 15, 310\u2013324 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"631_CR259","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet, J. M. et al. Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 19, 151\u2013172 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"631_CR260","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nature17040","volume":"529","author":"S Rafii","year":"2016","unstructured":"Rafii, S., Butler, J. M. & Ding, B. S. Angiocrine functions of organ-specific endothelial cells. Nature 529, 316\u2013325 (2016).","journal-title":"Nature"},{"key":"631_CR261","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16660","author":"L Perez-Gutierrez","year":"2022","unstructured":"Perez-Gutierrez, L., Li, P. & Ferrara, N. Endothelial cell diversity: the many facets of the crystal. FEBS J. https:\/\/doi.org\/10.1111\/febs.16660 (2022).","journal-title":"FEBS J."},{"key":"631_CR262","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114511","volume":"14","author":"P Li","year":"2022","unstructured":"Li, P. et al. LIF, a mitogen for choroidal endothelial cells, protects the choriocapillaris: implications for prevention of geographic atrophy. EMBO Mol. Med. 14, e14511 (2022).","journal-title":"EMBO Mol. Med."},{"key":"631_CR263","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","volume":"15","author":"N Ferrara","year":"2016","unstructured":"Ferrara, N. & Adamis, A. P. Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov. 15, 385\u2013403 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"631_CR264","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/08977199209023937","volume":"7","author":"KJ Kim","year":"1992","unstructured":"Kim, K. J., Li, B., Houck, K., Winer, J. & Ferrara, N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7, 53\u201364 (1992).","journal-title":"Growth Factors"},{"key":"631_CR265","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/362841a0","volume":"362","author":"KJ Kim","year":"1993","unstructured":"Kim, K. J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362, 841\u2013844 (1993).","journal-title":"Nature"},{"key":"631_CR266","first-page":"4593","volume":"57","author":"LG Presta","year":"1997","unstructured":"Presta, L. G. et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593\u20134599 (1997).","journal-title":"Cancer Res."},{"key":"631_CR267","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cell.2007.08.038","volume":"131","author":"C Fischer","year":"2007","unstructured":"Fischer, C. et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131, 463\u2013475 (2007).","journal-title":"Cell"},{"key":"631_CR268","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cell.2010.01.033","volume":"141","author":"C Bais","year":"2010","unstructured":"Bais, C. et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 141, 166\u2013177 (2010).","journal-title":"Cell"},{"key":"631_CR269","first-page":"49","volume":"8","author":"L Fala","year":"2015","unstructured":"Fala, L. Cyramza (ramucirumab) approved for the treatment of advanced gastric cancer and metastatic non-small-cell lung cancer. Am. Health Drug Benefits 8, 49\u201353 (2015).","journal-title":"Am. Health Drug Benefits"},{"key":"631_CR270","doi-asserted-by":"publisher","first-page":"43496","DOI":"10.1074\/jbc.M307742200","volume":"278","author":"D Lu","year":"2003","unstructured":"Lu, D. et al. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J. Biol. Chem. 278, 43496\u201343507 (2003).","journal-title":"J. Biol. Chem."},{"key":"631_CR271","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/sj.bjc.6605366","volume":"101","author":"R Kumar","year":"2009","unstructured":"Kumar, R. et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br. J. Cancer 101, 1717\u20131723 (2009).","journal-title":"Br. J. Cancer"},{"key":"631_CR272","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte, R. S., Chen, D. S. & Ferrara, N. VEGF in signaling and disease: beyond discovery and development. Cell 176, 1248\u20131264 (2019).","journal-title":"Cell"},{"key":"631_CR273","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","volume":"386","author":"V Makker","year":"2022","unstructured":"Makker, V. et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N. Engl. J. Med. 386, 437\u2013448 (2022).","journal-title":"N. Engl. J. Med."},{"key":"631_CR274","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","volume":"27","author":"TK Choueiri","year":"2021","unstructured":"Choueiri, T. K. et al. Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat. Med. 27, 802\u2013805 (2021).","journal-title":"Nat. Med."},{"key":"631_CR275","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-19-1459","volume":"26","author":"KD Courtney","year":"2020","unstructured":"Courtney, K. D. et al. HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma. Clin. Cancer Res. 26, 793\u2013803 (2020).","journal-title":"Clin. Cancer Res."},{"key":"631_CR276","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1167\/tvst.5.2.10","volume":"5","author":"N Ferrara","year":"2016","unstructured":"Ferrara, N. VEGF and intraocular neovascularization: from discovery to therapy. Transl. Vis. Sci. Technol. 5, 10 (2016).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"631_CR277","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","volume":"26","author":"N Ferrara","year":"2006","unstructured":"Ferrara, N., Damico, L., Shams, N., Lowman, H. & Kim, R. Developmemt of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26, 859\u2013870 (2006).","journal-title":"Retina"},{"key":"631_CR278","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1080\/03007995.2016.1221803","volume":"32","author":"H Vorum","year":"2016","unstructured":"Vorum, H., Olesen, T. K., Zinck, J. & Hedegaard, M. Real world evidence of use of anti-VEGF therapy in Denmark. Curr. Med. Res. Opin. 32, 1943\u20131950\u00a0(2016).","journal-title":"Curr. Med. Res. Opin."},{"key":"631_CR279","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003554","volume":"3","author":"M Saint-Geniez","year":"2008","unstructured":"Saint-Geniez, M. et al. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS ONE\u00a03, e3554 (2008).","journal-title":"PLoS ONE"},{"key":"631_CR280","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120231","volume":"3","author":"D Long","year":"2018","unstructured":"Long, D. et al. VEGF\/VEGFR2 blockade does not cause retinal atrophy in AMD-relevant models. JCI Insight 3, e120231\u00a0(2018).","journal-title":"JCI Insight"},{"key":"631_CR281","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1921252118","volume":"118","author":"H Xin","year":"2021","unstructured":"Xin, H. et al. Heparin-binding VEGFR1 variants as long-acting VEGF inhibitors for treatment of intraocular neovascular disorders. Proc. Natl Acad. Sci. USA 118, e1921252118\u00a0(2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"631_CR282","doi-asserted-by":"publisher","first-page":"eabq5241","DOI":"10.1126\/scitranslmed.abq5241","volume":"15","author":"AC Karle","year":"2023","unstructured":"Karle, A. C. et al. Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis\/retinal vascular occlusion adverse events. Sci. Transl Med. 15, eabq5241 (2023).","journal-title":"Sci. Transl Med."},{"key":"631_CR283","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s13300-023-01410-8","volume":"14","author":"S Sydnor","year":"2023","unstructured":"Sydnor, S. et al. Efficacy and safety of brolucizumab, aflibercept, and ranibizumab for the treatment of patients with visual impairment due to diabetic macular oedema: a systematic review and network meta-analysis. Diabetes Ther. 14, 1193\u20131216\u00a0(2023).","journal-title":"Diabetes Ther."},{"key":"631_CR284","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ophtha.2023.02.001","volume":"130","author":"TL Jackson","year":"2023","unstructured":"Jackson, T. L. et al. A randomized controlled trial of OPT-302, a VEGF-C\/D inhibitor for neovascular age-related macular degeneration. Ophthalmology 130, 588\u2013597\u00a0(2023).","journal-title":"Ophthalmology"}],"container-title":["Nature Reviews Molecular Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41580-023-00631-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41580-023-00631-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41580-023-00631-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T09:05:13Z","timestamp":1697792713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41580-023-00631-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":284,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["631"],"URL":"https:\/\/doi.org\/10.1038\/s41580-023-00631-w","relation":{},"ISSN":["1471-0072","1471-0080"],"issn-type":[{"value":"1471-0072","type":"print"},{"value":"1471-0080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]},"assertion":[{"value":"16 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.F. is a co-founder of Theia Therapeutics and NVasc. L.P.-G. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}